Literature DB >> 33576302

Telmisartan/hydrochlorothiazide-induced nevus-associated cutaneous melanoma: first report in the medical literature.

Georgi Tchernev1, James W Patterson2.   

Abstract

Introduction: The treatment of hypertension with certain groups of drugs may be problematic, particularly because certain drugs are capable of potentiating carcinogenesis. The presence of various receptors or components of the renin - angiotensin system in the skin, and particularly in melanocytes, determines the possible influence on this tissue by the so-called angiotensin receptor blockers or sartans. Thiazide diuretics can further influence the processes of carcinogenesis in all forms of skin cancer - melanocytic and non-melanocytic.Areas covered: We present a 67-year-old patient treated for a period of 3 years with a combined preparation containing Telmisartan/hydrochlorothiazide 80 mg/12.5 mg. Within 2 years, the patient observed the rapid development of a nevus that progressed to melanoma and was subsequently identified histopathologically as nevus-associated cutaneous melanoma with a 0.6 mm thickness, Clark IV. Following surgical treatment, no tumor progression has occurred to date. To our knowledge, this is the first reported case of a patient who developed a nevus-associated cutaneous melanoma after combination therapy with generic sartan and hydrochlorothiazide.Expert opinion: We discuss the diverse but mutually potentiating pro-carcinogenic effects of this class of agents, potentially leading to the development of cutaneous melanoma.

Entities:  

Keywords:  Telmisartan; drug mediated carcinogenesis; hydrochlorothiazide; melanoma progression; melanoma surgery

Mesh:

Substances:

Year:  2021        PMID: 33576302     DOI: 10.1080/17512433.2021.1890581

Source DB:  PubMed          Journal:  Expert Rev Clin Pharmacol        ISSN: 1751-2433            Impact factor:   5.045


  1 in total

1.  Hydrochlorothiazide: A savior to the heart or a foe to the skin?

Authors:  Ayush Kumar; Govinda Khatri; Sarya Swed; Mohammad Mehedi Hasan
Journal:  Ann Med Surg (Lond)       Date:  2022-06-09
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.